




PHARMACEUTICAL 2022

Homology Medicines Inc.
Rank 204 of 466





RealRate

PHARMACEUTICAL 2022

Homology Medicines Inc. Rank 204 of 466



The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Homology Medicines Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 77% points above the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 191,909 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 17,226 |
| Liabilities, Non-Current | 24,844 |
| Other Assets | 17,560 |
| Other Compr. Net Income | -7.0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 185 |
| Other Revenues | 33,971 |
| Property and Equipment | 2,252 |
| Research and Development | 93,085 |
| Selling, General and Administrative Expense | 36,835 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 211,721 |
| Liabilities | 42,070 |
| Expenses | 129,920 |
| Revenues | 33,971 |
| Stockholders Equity | 169,651 |
| Net Income | -95,764 |
| Comprehensive Net Income | -95,768 |
| Economic Capital Ratio | 154% |